At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
Decitabinedrug
Likely dose
Decitabine 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes
In Brief
A Phase 2 clinical trial evaluating Decitabine for Myelodysplastic Syndrome. Completed, enrolled 99 participants across 21 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
First PostedDec 2005
Primary CompletionJun 2008
Study CompletionDec 2008
TodayJul 2026
First PostedDec 1, 2005
Enrollment StartMay 1, 2005
Primary CompletionJun 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.6 years ago
Interventions
Decitabinedrug
20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.